Bio Ascend Launches Third Cohort of Lung Oncology Young Investigators Program
Bio Ascend, a part of the Vaniam Group, has recently initiated the third cohort of the Academy of Next Wave of Investigators™ program, an innovative initiative designed to cultivate the skills of early-career clinical investigators specializing in thoracic oncology. The program, which spans one year, combines both live and virtual seminars led by distinguished leaders in the field, providing invaluable mentorship and training to participants.
The program, which officially launched at a two-day conference in Atlanta on May 9-10, aims to empower young investigators by equipping them with essential tools necessary for advancing their research and improving patient care, particularly for those diagnosed with lung cancer. According to Kraig Steubing, Senior Vice President of Strategic Engagement at Vaniam Group, the Academy is committed to nurturing the next generation of leaders in thoracic oncology through expert guidance on various topics, including research innovation, grant acquisition, presentation skills, and leadership development.
During the initial conference, the keynote speeches and interactive sessions provided participants with key strategies and insights on enhancing research efforts. Following the event, each participant will benefit from ongoing mentorship sessions with faculty advisors, ensuring continuous growth and development. Additionally, participants will have the opportunity to network during the American Society of Clinical Oncology (ASCO) Annual Meeting in 2026, further enhancing collaboration among young investigators.
The Academy’s faculty team is made up of renowned experts in thoracic oncology who are dedicated to mentoring these early-career researchers. Their commitment not only promotes the individuals' careers but also aligns with Vaniam Group’s overarching mission of improving lung cancer care. Dr. Suresh Ramalingam, Executive Director of the Winship Cancer Institute of Emory University and Faculty Co-Chair of the program, emphasized the importance of the Academy in providing participants with critical skills necessary for impactful advancements in thoracic oncology.
This year's cohort includes 20 exceptional individuals who have been nominated by their fellowship directors or established leaders in the field. Among them are prominent figures such as Anuja Abhyankar from Roswell Park, Omar Abughanimeh from the University of Nebraska Medical Center, and Jacqueline Aredo from Stanford University, to name a few. These early-career investigators represent the future of lung cancer research, and their involvement in the Academy signifies a significant step forward in the fight against this devastating disease.
Moving forward, Bio Ascend and Vaniam Group are also planning future cohorts for the Academy, which will focus on researchers in hematologic malignancies and other oncologic fields. This initiative showcases their commitment to fostering talent and innovation in cancer research, ultimately benefiting patients and the medical community. Interested individuals can find more details on the program and faculty at www.bioascend.com/next-wave.
In summary, the Academy of Next Wave of Investigators™ stands as an essential platform for nurturing early-career professionals in thoracic oncology, granting them access to premier mentorship, training, and resources. With the support of Bio Ascend and Vaniam Group, these young investigators are well-positioned to lead future advancements in lung cancer care, ushering in new therapeutic strategies and improved patient outcomes.
The program, which officially launched at a two-day conference in Atlanta on May 9-10, aims to empower young investigators by equipping them with essential tools necessary for advancing their research and improving patient care, particularly for those diagnosed with lung cancer. According to Kraig Steubing, Senior Vice President of Strategic Engagement at Vaniam Group, the Academy is committed to nurturing the next generation of leaders in thoracic oncology through expert guidance on various topics, including research innovation, grant acquisition, presentation skills, and leadership development.
During the initial conference, the keynote speeches and interactive sessions provided participants with key strategies and insights on enhancing research efforts. Following the event, each participant will benefit from ongoing mentorship sessions with faculty advisors, ensuring continuous growth and development. Additionally, participants will have the opportunity to network during the American Society of Clinical Oncology (ASCO) Annual Meeting in 2026, further enhancing collaboration among young investigators.
The Academy’s faculty team is made up of renowned experts in thoracic oncology who are dedicated to mentoring these early-career researchers. Their commitment not only promotes the individuals' careers but also aligns with Vaniam Group’s overarching mission of improving lung cancer care. Dr. Suresh Ramalingam, Executive Director of the Winship Cancer Institute of Emory University and Faculty Co-Chair of the program, emphasized the importance of the Academy in providing participants with critical skills necessary for impactful advancements in thoracic oncology.
This year's cohort includes 20 exceptional individuals who have been nominated by their fellowship directors or established leaders in the field. Among them are prominent figures such as Anuja Abhyankar from Roswell Park, Omar Abughanimeh from the University of Nebraska Medical Center, and Jacqueline Aredo from Stanford University, to name a few. These early-career investigators represent the future of lung cancer research, and their involvement in the Academy signifies a significant step forward in the fight against this devastating disease.
Moving forward, Bio Ascend and Vaniam Group are also planning future cohorts for the Academy, which will focus on researchers in hematologic malignancies and other oncologic fields. This initiative showcases their commitment to fostering talent and innovation in cancer research, ultimately benefiting patients and the medical community. Interested individuals can find more details on the program and faculty at www.bioascend.com/next-wave.
In summary, the Academy of Next Wave of Investigators™ stands as an essential platform for nurturing early-career professionals in thoracic oncology, granting them access to premier mentorship, training, and resources. With the support of Bio Ascend and Vaniam Group, these young investigators are well-positioned to lead future advancements in lung cancer care, ushering in new therapeutic strategies and improved patient outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.